Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Richez · SciRah

Researcher profile · Semantic Scholar

V. Richez

Share profile

V. Richez — researcher profile on SciRah

h-index: 14
Works: 55
Citations: 565

Most-cited papers

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.
A. Perrot, V. Lauwers-Cancès, E. Tournay, C. Hulin +25 more
2019Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
A. Jurczyszyn, J. Radocha, J. Dávila, M. Fiala +30 more
2018British Journal of Haematology61 citations Open access
Semantic Scholar
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial.
A. Perrot, C. Touzeau, J. Lambert, C. Hulin +47 more
2025Blood42 citations Open access
Semantic Scholar
EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE.
A. Caulier, M. Roussel, P. Morel, N. Lombion +22 more
2021Blood25 citations Open access
Semantic Scholar
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
A. Schavgoulidze, A. Perrot, X. Leleu, T. Cazaubiel +37 more
2025Blood23 citations Open access
Semantic Scholar
Response to pneumococcal vaccination in multiple myeloma
L. Renaud, S. Schraen, G. Fouquet, S. Guidez +21 more
2019Cancer Medicine23 citations Open access
Semantic Scholar
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
Mohamed-Amine Hamouda, A. Jacquel, G. Robert, A. Puissant +27 more
2016Journal of Experimental Medicine22 citations Open access
Semantic Scholar
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
Felicity Kendrick, N. Evans, B. Arnulf, H. Avet-Loiseau +14 more
2017Frontiers in Physiology21 citations Open access
Semantic Scholar
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
J. Corre, A. Perrot, C. Hulin, D. Caillot +25 more
2021Leukemia20 citations Open access
Semantic Scholar
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
M. Roussel, V. Lauwers-Cancès, M. Macro, X. Leleu +55 more
2022Blood19 citations Open access
Semantic Scholar
Monosomal karyotype improves IPSS‐R stratification in MDS and AML patients treated with Azacitidine
T. Cluzeau, N. Mounier, J. Karsenti, V. Richez +10 more
2013American journal of hematology/oncology19 citations Open access
Semantic Scholar
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
S. Manier, J. Lambert, C. Hulin, M. Macro +36 more
2025The Lancet Oncology18 citations Open access
Semantic Scholar
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies
L. Drevon, A. Marceau, O. Maarek, W. Cuccuini +22 more
2018British Journal of Haematology18 citations
Semantic Scholar
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
G. Fouquet, S. Guidez, V. Richez, A. Stoppa +19 more
2018OncoTarget15 citations Open access
Semantic Scholar
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
X. Leleu, G. Fouquet, V. Richez, S. Guidez +37 more
2019Clinical Cancer Research14 citations
Semantic Scholar
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
G. Fouquet, B. Pégourié, M. Macro, M. Petillon +25 more
2016Annals of Oncology12 citations Open access
Semantic Scholar
RAS/RAFlandscape in monoclonal plasma cell conditions.
A. Schavgoulidze, J. Corre, M. Samur, C. Mazzotti +23 more
2024Blood10 citations Open access
Semantic Scholar
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
C. Touzeau, X. Leleu, M. Tiab, M. Macro +22 more
2025British Journal of Haematology9 citations Open access
Semantic Scholar
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
M. Macro, C. Hulin, L. Vincent, A. Charvet-Rumpler +13 more
2023Annals of Hematology8 citations Open access
Semantic Scholar
Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
V. Richez, Cécile Gruchet, S. Guidez, G. Fouquet +28 more
2018American journal of hematology/oncology7 citations
Semantic Scholar
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
G. Fouquet, K. Snell, S. Guidez, S. Schraen +26 more
2018Leukemia and Lymphoma7 citations
Semantic Scholar
RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort?
O. Decaux, A. Perrot, L. Frenzel, B. Royer +18 more
2021Blood4 citations Open access
Semantic Scholar
Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study
L. Clément-Filliatre, L. Benboubker, A. Stoppa, P. Rodon +13 more
20204 citations Open access
Semantic Scholar
High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
J. Corre, J. Lambert, A. Bobin, S. Manier +49 more
2024Blood3 citations
Semantic Scholar
Reactive angioendotheliomatosis revealing a glomerulopathy secondary to a monoclonal gammopathy successfully treated with lenalidomide
Y. Di Filippo, N. Cardot-Leccia, Elodie Long-Mira, M. Andreani +4 more
2020Journal of the European Academy of Dermatology and Venereology3 citations
Semantic Scholar
Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study
Fressia Honeyman, E. Tavernier, V. Richez, T. Leguay +17 more
20163 citations
Semantic Scholar
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort.
T. Chalopin, M. Macro, O. Decaux, B. Royer +21 more
2024Clinical Lymphoma, Myeloma & Leukemia2 citations Open access
Semantic Scholar
Posterior Reversible Encephalopathy Syndrome During Induction Treatment ofPhiladelphia Positive Acute Lymphoblastic Leukemia in an Adult Patient: FirstCase Report and Literature Review
J. Reure, F. Peyrade, C. Lebrun-Frénay, J. Dellamonica +6 more
20152 citations Open access
Semantic Scholar
Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)
A. Bobin, J. Lambert, J. Corre, S. Manier +34 more
2025Blood1 citations
Semantic Scholar
All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.
C. Touzeau, X. Leleu, M. Tiab, M. Macro +16 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
A. Bobin, S. Manier, J. de Keizer, L. Karlin +29 more
2022HemaSphere1 citations Open access
Semantic Scholar
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
A. Bobin, M. Kyheng, S. Guidez, Cécile Gruchet-Merouze +38 more
2021Leukemia1 citations
Semantic Scholar
Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
V. Richez, S. Guidez, I. Azais, G. Durand +16 more
20181 citations
Semantic Scholar
Impact of Pneumococcal Vaccination on Multiple Myeloma
L. Renaud, S. Schraen, G. Fouquet, S. Guidez +18 more
20171 citations
Semantic Scholar
Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients
C. Herbaux, Cristina João, A. Plocque, V. Richez +24 more
20141 citations
Semantic Scholar
Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.
T. Cluzeau, N. Mounier, V. Richez, J. Karsenti +13 more
20121 citations
Semantic Scholar
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.
T. Chalopin, O. Decaux, C. Hulin, A. Perrot +21 more
2025Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
OA-61 All Oral Triplet Iberdomide Ixazomib and Dexamethasone in Elderly Patients With Multiple Myeloma Patients at First Relapse: Results of the IFM Phase 2 Study I2D
C. Touzeau, X. Leleu, M. Tiab, M. Macro +19 more
2024Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
A. Bobin, S. Manier, J. de Keizer, C. Hulin +29 more
2023Blood0 citations Open access
Semantic Scholar
PS1406 WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA
C. Gruchet, V. Richez, S. Guidez, C. Tomowiak +14 more
2019HemaSphere0 citations Open access
Semantic Scholar
Weekly 20/56mg/m2 Carfilzomib, Lenalidomide and Dexamethasone until progression in Early Relapsed Refractory Multiple Myeloma
Cécile Gruchet, V. Richez, S. Guidez, Florence Sabirou +11 more
2019Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Pomalidomide 3rd line versus 4th line for in Early Relapsed Refractory Multiple Myeloma
Cécile Gruchet, S. Guidez, C. Tomowiak, Florence Sabirou +12 more
2019Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma.
Cécile Gruchet, V. Richez, S. Guidez, G. Fouquet +16 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
V. Richez, Cécile Gruchet, S. Guidez, G. Fouquet +28 more
2018Blood0 citations Open access
Semantic Scholar
Large retrospective study of lenalidome-dexamethasone (Rd) in patients older than 80 with multiple myeloma (MM): Is less more?
M. Tardy, B. Slama, J. Doyen, A. Stoppa +8 more
20180 citations
Semantic Scholar
Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma
Cécile Gruchet, S. Guidez, G. Fouquet, I. Azais +28 more
2018Blood0 citations Open access
Semantic Scholar
Pomalidomide 3rd Line Versus 4th Line for RRMM
Cécile Gruchet, S. Guidez, V. Richez, C. Hulin +30 more
2018Blood0 citations Open access
Semantic Scholar
Autoévaluations de l'article : Myélome multiple
G. Fouquet, Stéphanie Guidez, V. Richez, Thomas Systchenko +8 more
20170 citations
Semantic Scholar
Time to Improve Bortezomib and Lenalidomide Lines of Therapy
S. Guidez, H. Demarquette, D. Caillot, A. Jurczyszyn +22 more
20170 citations
Semantic Scholar
MDS with Isolated Trisomy 8: A type of MDS Frequently Associated with Myeloproliferative Features? A Report by the GFM
L. Drevon, Aline Renneville, A. Marceau, S. Raynaud +16 more
20170 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

X. Leleu×28
Invite
X. Leleu — researcher profile on SciRah
C. Hulin×25
Invite
C. Hulin — researcher profile on SciRah
A. Bobin×21
Invite
A. Bobin — researcher profile on SciRah
M. Macro×19
Invite
M. Macro — researcher profile on SciRah

×18

Invite

Lionel Karlin — researcher profile on SciRah

H. Avet-Loiseau×17

Invite

H. Avet-Loiseau — researcher profile on SciRah

Invite

S. Guidez — researcher profile on SciRah

Invite

A. Perrot — researcher profile on SciRah

Invite

D. Caillot — researcher profile on SciRah

Invite

S. Manier — researcher profile on SciRah

Invite

G. Fouquet — researcher profile on SciRah

Invite

T. Facon — researcher profile on SciRah